Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVE: Dostarlimab ± Bevacizumab vs Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma
KCT0008758Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab, bevacizumab in Clear-cell gynecological cancer, sponsored by GSK. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
dostarlimabbevacizumab
03
Conditions
Clear-cell gynecological cancer
Beyond the preview
Go deeper on KCT0008758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008758.